EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Management and Prognosis of HCC Patients With Elevated Tumor Markers but no Imaging Recurrence After Radiofrequency Ablation

Makoto Moriyama iD, Ryosuke Tateishi iD, Yuki Matsushita, Tomoharu Yamada, Takuma Nakatsuka iD, Tatsuya Minami, Masaya Sato iD, Shuichiro Shiina, Kazuhiko Koike, Mitsuhiro Fujishiro iD

Cancer Medicine · 2026-04 · 15 (4)

DOI: 10.1002/cam4.71812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.04.2026. Verfasst von Makoto Moriyama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Tokyo University Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Biomarkers, Tumor, Carcinoma, Hepatocellular, Radiofrequency Ablation. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Welfare Policy Research Grants from the Ministry of Health, Labour and Welfare of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims HCC frequently recurs after curative treatment, requiring surveillance with imaging and tumor markers. Some patients, however, present with persistent tumor marker elevation despite no radiologic recurrence evidence. This study evaluated outcomes following radiofrequency ablation (RFA) in such cases.

Methods

We retrospectively analyzed 1620 patients who achieved complete ablation for primary HCC during 1999–2015. Surveillance included quarterly imaging and serum tumor markers, alpha‐fetoprotein (AFP), lens culinaris agglutinin‐reactive fraction of AFP (AFP‐L3), and des‐gamma‐carboxy prothrombin (DCP). Patient characteristics at tumor marker elevation and recurrent HCC characteristics were compared between the early recurrence group (recurrence within 180 days of tumor marker elevation) and the late recurrence group (recurrence after 180 days of tumor marker elevation). We also estimated post‐recurrence survival using the Kaplan–Meier method.

Results

Tumor marker elevation occurred in 907 cases in 509 patients. Recurrence was detected in 886 cases: 707 in the early and 179 in the late recurrence groups. The median (interquartile range) interval between marker elevation and recurrence was 89.0 (81.0–97.0) days. At tumor marker elevation, AFP ≥ 20 ng/mL was more frequent in the early versus late recurrence group (71.0% vs. 58.1%, p < 0.01), as was AFP ≥ 200 ng/mL (29.4% vs. 20.1%, p = 0.02). AFP‐L3 ≥ 15% (60.0% vs. 62.6%, p = 0.58) and DCP ≥ 200 mAU/mL (19.7% vs. 16.2%, p = 0.34) showed no significant differences between groups. Recurrence patterns, including number of tumors, vascular invasion, distant metastasis, and tumor size, were comparable between groups. Local cure was achieved in 83.5% and 78.8% of the early and late recurrence groups, respectively, with no significant difference ( p = 0.17). Median post‐recurrence survival was 3.55 years for the early versus 3.31 years for the late recurrence group ( p = 0.2).

Conclusions

Even when HCC was undetected on imaging despite elevated tumor markers, many recurrence cases were subsequently detected, and curative treatment was possible through appropriate surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsBiomarkers, TumorCarcinoma, HepatocellularRadiofrequency AblationNeoplasm Recurrence, LocalHumansFemalePrognosisMaleRetrospective Studiesalpha-FetoproteinsMiddle AgedAgedProtein PrecursorsProthrombinTreatment OutcomeKaplan-Meier EstimateBiomarkers

Stichwörter der Autor:innen

AFPAFP‐L3DCPbiomarkerimaging

Substanzen

Biomarkers, Tumoralpha-FetoproteinsacarboxyprothrombinProtein PrecursorsProthrombinBiomarkers

Autor:innen und Institutionen

  • Department of Gastroenterology, Tokyo University Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Gastroenterology, Juntendo University Hospital, Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Kanto Central Hospital, Public Schools Mutual Aid Association, Tokyo, Japan.

ORCID-Profile: Makoto Moriyama, Ryosuke Tateishi, Takuma Nakatsuka, Masaya Sato, Mitsuhiro Fujishiro

Förderung

  • Japan Agency for Medical Research and Development
  • Welfare Policy Research Grants from the Ministry of Health, Labour and Welfare of Japan

Zitieren

APA

Moriyama, M., Tateishi, R., Matsushita, Y., Yamada, T., Nakatsuka, T., Minami, T., Sato, M., Shiina, S., Koike, K., & Fujishiro, M. (2026). Management and Prognosis of HCC Patients With Elevated Tumor Markers but no Imaging Recurrence After Radiofrequency Ablation. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71812

Vancouver

Moriyama M, Tateishi R, Matsushita Y, Yamada T, Nakatsuka T, Minami T, et al. Management and Prognosis of HCC Patients With Elevated Tumor Markers but no Imaging Recurrence After Radiofrequency Ablation. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71812

BibTeX
@article{Moriyama2026,
  author = {Moriyama, Makoto and Tateishi, Ryosuke and Matsushita, Yuki and Yamada, Tomoharu and Nakatsuka, Takuma and Minami, Tatsuya and Sato, Masaya and Shiina, Shuichiro and Koike, Kazuhiko and Fujishiro, Mitsuhiro},
  title = {Management and Prognosis of HCC Patients With Elevated Tumor Markers but no Imaging Recurrence After Radiofrequency Ablation},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cam4.71812}
}
Kostenlos starten →